Is in vitro expansion of human cord blood cells clinically relevant?

Peripheral blood recovery after cord blood (CB) transplantation is delayed compared with marrow, Expansion of CB haemopoietic cells has been investigated with the aim of reducing cytopenia following transplantation. Mature cells, post-progenitors, progenitors and longterm culture-initiating cells (LTC-IC) from expansion products may contribute to peripheral blood recovery, We investigated the increase in total nucleated cells, colony-forming cells (CFC), CD34(+) cells and LTC-IC by limiting dilution after a 14 day culture of CB CD34(+) cells (5 x 10(3)/ml) with SCF, IL-3, IL-6, GM-CSF and G-CSF all at 10 ng/ml, On average, nucleated cells increased 2500-fold, CD34(+) cells 39-fold and CFU-GM 49-fold with maintenance of BFU-E, The more primitive LTC-IC expanded on average 2.5-fold but effects on long-term marrow-repopulating cells (LTRC) during culture are unknown, A practical application of in vitro expansion of CB might be to expand a 20% aliquot of a CB donation and infuse the remainder unmanipulated, This could provide a 5- to 7-fold increase in progenitor cells, an estimated 1570-fold increase in post-progenitor cells and maintenance of LTC-IC compared to an untreated donation, Combined with in vivo posttransplant growth factor therapy this could prompt early peripheral blood recovery after CB transplantation, without significant loss of LTC-IC or donor lymphocytes.